Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27719894 | 0.92 | CASP3 (0.48) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29477082 | 0.90 | CASP3 (0.47) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29696659 | 0.90 | CASP3 (0.45) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29539802 | 0.89 | CASP3 (0.50) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29696727 | 0.85 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL2591012 | 0.85 | CASP3 (0.58) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL31697682 | 0.85 | CASP3 (0.60) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL120703 | 0.85 | CASP3 (0.60) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL799720 | 0.85 | CASP3 (0.60) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL178791 | 0.85 | CASP3 (0.60) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025100405-A1 | MACROCYCLIC PEPTIDE COMPOUND HAVING CELL MEMBRANE PERMEABILITY AND METABOLIC STABILITY, AND LIBRARY CONTAINING SAME | 中外製薬株式会社 | 2025-05-15 | — | — | WO | disclosed |
| CN-114630835-B | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| CN-116615411-A | Process for producing peptide compound containing N-substituted amino acid residue | 中外制药株式会社 | 2023-08-18 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4144747-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698032-A | Efficient peptide condensation of difficult sequences | 中外制药株式会社 | 2023-02-03 | — | — | CN | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4056580-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-14 | — | — | EP | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CASP3 3906/4885MDM4 441/4885TP53 34/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CASP3 3906/4885MDM4 441/4885TP53 34/4885 |
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | CASP3 3884/4885MDM4 2608/4885TP53 4118/4885 |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | CASP3 1864/4885MDM4 3528/4885TP53 1753/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | CASP3 1864/4885MDM4 3528/4885TP53 1753/4885 |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | CASP3 4334/4885MDM4 794/4885TP53 410/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CASP3 3906/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.